Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IdeS for Desensitization in Kidney Transplant
NCT02790437Phase 2Completed
- Sponsor
- Hansa Biopharma
- Start
- Jun 2016
- Primary completion
- Dec 2017
- Modality
- Therapeutic Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of imlifidase in sensitization in kidney transplantation (PRA), sponsored by Hansa Biopharma. Primary endpoint: Number of Patients With Crossmatch Conversion (Positive to Negative) at 24 hours. Started Jun 2016; status: completed.
02
Drugs
imlifidase
03
Conditions
sensitization in kidney transplantation (PRA)
Beyond the preview
Go deeper on NCT02790437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790437.